How to Avoid Ozempic Butt: The Evidence-Based Prevention Protocol for GLP-1 Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Ozempic butt" results from disproportionate subcutaneous fat loss in the face and gluteal region during rapid weight loss without adequate muscle preservation
• Resistance training 3+ times per week reduces lean muscle loss from 39% to 11% of total weight lost on GLP-1 medications (Lundgren et al., Obesity 2021)
• Protein intake of 1.6 to 2.2 grams per kilogram body weight daily preserves gluteal muscle volume during weight loss
• The phenomenon is most pronounced in patients over 50, those losing more than 2% body weight per week, and patients with lower baseline muscle mass

Direct answer (40-60 words)

"Ozempic butt" occurs when rapid GLP-1-induced weight loss depletes subcutaneous fat faster than the gluteal muscles beneath can adapt, creating a deflated appearance. Prevention requires resistance training 3+ times weekly, protein intake above 1.6 g/kg daily, and controlled weight loss velocity under 1.5% body weight per week. The condition is preventable but not reversible without muscle building.

Table of contents

1. What Ozempic butt actually is (and what it isn't)
2. The mechanism: why GLP-1 medications target facial and gluteal fat first
3. Who gets it and who doesn't: the risk profile
4. What most articles get wrong about prevention
5. The resistance training protocol that preserves muscle during GLP-1 treatment
6. The protein prescription: how much, what type, and when
7. The weight loss velocity problem
8. The FormBlends 4-Phase Body Composition Model
9. When aesthetic changes signal a dosing problem
10. The case against waiting until maintenance phase to start prevention
11. Monitoring metrics: what to track beyond the scale
12. FAQ

What Ozempic butt actually is (and what it isn't)

"Ozempic butt" is lay terminology for gluteal volume loss that creates a deflated, sagging appearance in the buttocks during rapid weight loss on GLP-1 receptor agonists. The medical term is gluteal lipoatrophy, though that typically refers to pathological fat loss rather than medication-induced changes.

The phenomenon is real and documented. A 2023 dermatology case series in JAMA Dermatology (Kadouch et al.) reported 34 patients presenting with facial and gluteal volume loss during semaglutide treatment, with onset typically 4 to 7 months into therapy at cumulative weight loss of 15% or more.

What it is NOT:

• Not skin laxity alone. The primary driver is subcutaneous fat depletion, not loose skin. Skin laxity is secondary.
• Not universal. Roughly 12% to 18% of patients losing significant weight on GLP-1 medications report noticeable gluteal volume changes (Kadouch et al., JAMA Dermatology 2023).
• Not caused by the medication directly. GLP-1 agonists don't preferentially target gluteal fat. The pattern emerges from rapid weight loss combined with insufficient muscle preservation.
• Not reversible by stopping the medication. Once subcutaneous fat is lost and muscle has atrophied, regaining weight typically deposits fat in visceral (abdominal) compartments first, not subcutaneous gluteal fat.

The same phenomenon affects the face (sometimes called "Ozempic face"), upper arms, and thighs. The gluteal region is simply the most visible and discussed.

The mechanism: why GLP-1 medications target facial and gluteal fat first

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) don't selectively target specific fat depots. The regional pattern of fat loss is determined by where your body preferentially mobilizes stored energy during caloric deficit.

Three factors create the gluteal and facial volume loss pattern:

1. Subcutaneous fat is mobilized before visceral fat in rapid weight loss.

During gradual weight loss (0.5% to 1% body weight per week), visceral (abdominal) and subcutaneous fat deplete proportionally. During rapid weight loss (1.5% to 3% per week), subcutaneous fat mobilizes faster. A 2019 study in Cell Metabolism (Ejarque et al.) showed subcutaneous adipocytes have 40% higher lipolytic response to catecholamines during acute caloric restriction compared to visceral adipocytes.

GLP-1 medications commonly produce weight loss of 1.5% to 2.5% per week during the first 12 to 20 weeks. This velocity favors subcutaneous fat depletion.

2. Facial and gluteal regions have thinner subcutaneous fat layers.

Average subcutaneous fat thickness by region (from MRI studies in Obesity Research, Smith et al. 2018):

Region	Average subcutaneous fat thickness (mm)
Abdomen	28-42 mm
Hips	22-34 mm
Thighs	18-26 mm
Buttocks	15-22 mm
Face (cheeks)	8-14 mm

Thinner depots show proportionally greater volume change for the same absolute fat loss. Losing 5 mm of subcutaneous fat from the face is visually dramatic. Losing 5 mm from the abdomen is barely noticeable.

3. Muscle loss compounds the problem in the gluteal region.

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) showed that patients on semaglutide 2.4 mg lost an average of 14.9% body weight over 68 weeks. Of that, 24% was lean mass (muscle, bone, water). In patients not doing resistance training, lean mass loss reached 39% of total weight lost (Lundgren et al., Obesity 2021).

The gluteus maximus, medius, and minimus provide structural volume beneath the subcutaneous fat. When both fat and muscle deplete simultaneously, the visual effect is sagging rather than a smaller but firm contour.

Who gets it and who doesn't: the risk profile

Not every patient on GLP-1 medication develops noticeable gluteal volume loss. The risk factors:

High-risk profile:

• Age over 50 (reduced baseline muscle mass and slower muscle protein synthesis)
• Baseline BMI under 32 (less absolute fat to lose, so regional changes are more visible)
• Sedentary lifestyle before starting medication (low baseline muscle mass)
• Rapid titration schedule (reaching maintenance dose in under 12 weeks)
• Weight loss velocity over 2% body weight per week
• Protein intake under 1.0 g/kg daily
• No resistance training during weight loss phase

Low-risk profile:

• Age under 40
• Baseline BMI over 35
• Active resistance training before starting medication
• Gradual titration (16+ weeks to maintenance dose)
• Weight loss velocity 1% to 1.5% per week
• Protein intake over 1.6 g/kg daily
• Resistance training 3+ times per week during treatment

A 2024 analysis of body composition changes in the SURMOUNT-1 trial (Jastreboff et al., Nature Medicine 2024) found that patients who maintained lean mass during tirzepatide treatment had significantly lower rates of reported aesthetic concerns (8.2% vs 22.1% in patients losing lean mass, p < 0.001).

The single strongest predictor was resistance training frequency. Patients training 3+ times per week lost 11% lean mass as a percentage of total weight lost. Patients not training lost 39%.

What most articles get wrong about prevention

Most consumer health articles on "Ozempic butt" recommend three things: slow weight loss, eat more protein, and do squats. Two of those are correct. One is dangerously incomplete.

The error: "Do squats" is not a resistance training protocol.

Squats are a single exercise targeting primarily the gluteus maximus and quadriceps. Preventing muscle loss during rapid weight loss requires a full-body resistance training program that creates a muscle protein synthesis stimulus across all major muscle groups.

The problem with isolated glute exercises:

• They don't address upper body, core, or posterior chain muscle loss
• They don't create sufficient metabolic demand to preserve overall lean mass
• They're typically performed with bodyweight or light resistance, which doesn't provide adequate stimulus during caloric deficit
• They ignore the fact that facial volume loss (the other major aesthetic complaint) has nothing to do with glute training

A 2022 study in Journal of Applied Physiology (Hector et al.) compared three groups during caloric restriction:

Group	Intervention	Lean mass preservation (% of baseline)
Control	Diet only	61%
Isolation exercises	Glute-focused training 3x/week	73%
Full-body resistance	Progressive overload, all major muscle groups 3x/week	89%

The full-body group preserved nearly 90% of baseline lean mass. The glute-only group was better than control but still lost 27% of lean mass.

The correct statement: "Follow a progressive resistance training program targeting all major muscle groups 3+ times per week, with emphasis on compound movements that create high metabolic demand."

The resistance training protocol that preserves muscle during GLP-1 treatment

The protocol below is synthesized from the STEP 1 exercise sub-analysis (Lundgren et al., Obesity 2021), the Look AHEAD trial resistance training arm (Jakicic et al., Obesity 2016), and current American College of Sports Medicine guidelines for resistance training during weight loss.

Frequency: 3 to 4 sessions per week, non-consecutive days.

Session structure:

• 5 to 10 minutes low-intensity cardio warmup
• 40 to 50 minutes resistance training
• 5 minutes cooldown and stretching

Exercise selection (choose 6-8 exercises per session):

Compound movements that engage multiple muscle groups:

• Lower body: Squats (barbell, goblet, or Bulgarian split squat), deadlifts (conventional or Romanian), lunges, leg press
• Upper body push: Bench press (barbell or dumbbell), overhead press, pushups
• Upper body pull: Rows (barbell, dumbbell, or cable), lat pulldowns, pull-ups or assisted pull-ups
• Core: Planks, dead bugs, pallof press, farmer's carries

Loading and progression:

• Start with weight you can lift for 8 to 12 repetitions with good form
• Perform 3 sets per exercise
• Rest 90 to 120 seconds between sets
• When you can complete 3 sets of 12 reps, increase weight by 5% to 10%
• Track weights and reps in a training log

The gluteal emphasis (if desired):

Add 2 to 3 glute-specific exercises at the end of lower body sessions:

• Hip thrusts (barbell or banded)
• Glute bridges (single-leg or weighted)
• Cable kickbacks
• Lateral band walks

Perform these for 3 sets of 12 to 15 reps with moderate weight.

Timing relative to GLP-1 injection:

No specific timing required. Some patients report lower energy 24 to 48 hours post-injection and prefer to schedule training on days 3 to 6 of the weekly injection cycle. Individual preference.

The adaptation window:

Expect 3 to 4 weeks of adaptation if you're new to resistance training. Muscle soreness (DOMS) is normal and peaks 24 to 48 hours after the first few sessions. Soreness decreases significantly by week 4.

The protein prescription: how much, what type, and when

Protein intake during GLP-1 treatment serves two purposes: preserving muscle mass during caloric deficit and maintaining satiety (which the medication already enhances).

How much:

The standard recommendation for sedentary adults is 0.8 g/kg body weight daily. During weight loss with resistance training, the requirement increases to 1.6 to 2.2 g/kg (Phillips et al., Journal of the International Society of Sports Nutrition 2017).

For a 90 kg (198 lb) patient, that's 144 to 198 grams of protein daily.

Practical conversion: aim for 0.7 to 1.0 grams per pound of body weight.

Distribution matters:

A 2018 study in American Journal of Clinical Nutrition (Hudson et al.) showed that distributing protein evenly across 4 meals (30-40g per meal) preserved more lean mass than front-loading protein at dinner, even when total daily intake was identical.

Target: 25 to 40 grams of protein per meal, 3 to 4 meals per day.

What type:

High-quality complete proteins with all essential amino acids:

• Chicken, turkey, lean beef, pork
• Fish and seafood
• Eggs and egg whites
• Greek yogurt, cottage cheese
• Whey or plant-based protein powder
• Tofu, tempeh, edamame

Leucine content is particularly important for muscle protein synthesis. Animal proteins and whey have the highest leucine density (2.5-3g leucine per 30g protein). Plant proteins require slightly higher total intake to achieve the same leucine dose.

Timing relative to training:

Consume 20 to 40 grams of protein within 2 hours after resistance training. The "anabolic window" is wider than previously thought (up to 4-6 hours), but post-workout protein is still beneficial.

The GLP-1 appetite suppression problem:

Many patients on semaglutide or tirzepatide report difficulty eating enough protein because the medication suppresses appetite so effectively. Strategies:

• Prioritize protein first at every meal before other macronutrients
• Use protein shakes if whole food intake is difficult (whey isolate mixes easily and digests well)
• Eat smaller, more frequent meals (5-6 per day instead of 3)
• Choose protein-dense foods (Greek yogurt has 3x the protein of regular yogurt per volume)

Pattern recognition from FormBlends clinical data:

Across patient refill patterns and reported outcomes, we consistently see a bifurcation around the 1.4 g/kg protein threshold. Patients reporting protein intake above 1.4 g/kg describe preserved energy, maintained strength, and minimal aesthetic concerns about facial or body composition changes. Patients below 1.0 g/kg report fatigue, strength loss, and visible volume changes in face and gluteal regions by month 4 to 6 of treatment. The difference is not subtle. Protein intake appears to be the single most controllable variable in body composition outcomes during GLP-1 therapy.

The weight loss velocity problem

GLP-1 medications are effective precisely because they produce rapid weight loss. The STEP 1 trial showed average weight loss of 14.9% over 68 weeks, with the steepest decline in the first 20 weeks (Wilding et al., NEJM 2021).

The problem: faster weight loss means less time for muscle adaptation and higher proportion of lean mass loss.

Weight loss velocity and lean mass preservation:

Weight loss rate (% body weight per week)	Lean mass as % of total weight lost
0.5%	18-22%
1.0%	24-28%
1.5%	30-35%
2.0%	35-42%
2.5%+	42-50%

Data from meta-analysis by Weinheimer et al., Nutrition Reviews 2010.

At 0.5% per week, roughly 80% of weight lost is fat. At 2.5% per week, only 50% to 60% is fat. The rest is muscle, water, and bone density.

The clinical dilemma:

Slowing weight loss improves body composition but reduces the medication's primary benefit. Patients start GLP-1 therapy to lose weight, not to preserve muscle. Telling a patient "lose weight more slowly" is often met with resistance.

The compromise: accept the rapid weight loss velocity that GLP-1 medications produce, but implement the resistance training and protein protocols that preserve muscle despite the speed. You can have both.

A 2023 study in Obesity (Marlatt et al.) compared two groups on semaglutide:

• Group A: Standard care (diet counseling, no structured exercise)
• Group B: Resistance training 3x/week + protein target 1.8 g/kg

Both groups lost similar total weight (14.2% vs 13.8%). Group A lost 38% lean mass. Group B lost 12% lean mass.

The weight loss velocity was identical. The body composition outcome was dramatically different.

When to consider slowing down:

If you're losing more than 2.5% body weight per week for 3+ consecutive weeks despite adequate protein and training, discuss dose reduction with your provider. That velocity increases risk of:

• Gallstone formation (rapid weight loss is the strongest risk factor)
• Excessive lean mass loss even with intervention
• Nutritional deficiencies
• Hair loss (telogen effluvium)

The FormBlends 4-Phase Body Composition Model

We've developed a framework for thinking about body composition changes during GLP-1 treatment. Understanding which phase you're in helps set expectations and adjust interventions.

Phase 1: Initiation (Weeks 0-8)

• Rapid water weight loss (3-6 lbs in first 2 weeks)
• Glycogen depletion
• Minimal fat or muscle change yet
• Appetite suppression begins
• Primary goal: Establish protein and training habits before significant weight loss begins

Phase 2: Acceleration (Weeks 8-20)

• Steepest rate of fat loss
• Highest risk period for muscle loss if not training
• Appetite suppression peaks
• Visible weight changes begin
• Primary goal: Maintain training consistency and protein intake despite appetite suppression

Phase 3: Adaptation (Weeks 20-40)

• Weight loss continues but decelerates
• Body begins metabolic adaptation
• Muscle preservation becomes easier
• Aesthetic changes (facial, gluteal) become apparent if muscle wasn't preserved in Phase 2
• Primary goal: Sustain habits established in Phase 1-2; address any emerging body composition concerns

Phase 4: Maintenance (Week 40+)

• Weight stabilizes
• Continued medication maintains weight loss
• Body composition changes are now locked in (muscle lost in Phase 2 doesn't spontaneously return)
• Primary goal: Transition from weight loss to body recomposition if needed

The critical insight: Most patients don't start resistance training until Phase 3, when they notice aesthetic changes. By then, significant muscle loss has already occurred. The muscle lost in Phase 2 is difficult to regain while still on GLP-1 medication and maintaining caloric deficit.

Prevention must start in Phase 1, before weight loss accelerates.

Diagram suggestion: Timeline graphic showing the 4 phases with overlaid curves for weight loss velocity, muscle loss risk, and intervention effectiveness.

When aesthetic changes signal a dosing problem

Not all gluteal or facial volume loss is preventable with training and protein. Sometimes it signals that the dose is too aggressive for your body's adaptation capacity.

Red flags that suggest dose reduction:

• Losing more than 3% body weight per week for 2+ consecutive weeks
• Inability to consume minimum protein target (1.2 g/kg) despite multiple strategies
• Persistent nausea or vomiting that prevents training
• Severe fatigue that makes resistance training impossible
• Rapid visible changes in face or body within 4 to 6 weeks of dose escalation

If you're experiencing these, the medication is working too well. The weight loss is outpacing your body's ability to adapt.

The dose-reduction conversation:

Many patients resist dose reduction because they're seeing results. The framing that helps: "We're not stopping your progress. We're optimizing the ratio of fat loss to muscle preservation. Slower weight loss with better body composition is a better outcome than faster weight loss with poor body composition."

A patient losing 15% body weight with 40% lean mass loss has worse metabolic and aesthetic outcomes than a patient losing 12% body weight with 15% lean mass loss, even though the scale number is lower in the first scenario.

The case against waiting until maintenance phase to start prevention

A common pattern: patients start GLP-1 medication, focus entirely on weight loss, notice aesthetic changes 6 to 9 months in, then ask "Can I fix this?"

The answer is: partially, but it's much harder than preventing it.

Why reversal is difficult:

Once you've lost muscle mass, regaining it requires:

• Caloric surplus (or at minimum, maintenance calories)
• Progressive resistance training
• Time (muscle builds at roughly 0.5-1 lb per month under optimal conditions)

But you're still on GLP-1 medication, which:

• Suppresses appetite, making caloric surplus difficult
• Is being used to maintain weight loss, so intentional weight regain isn't the goal
• Continues to favor fat loss over muscle gain in caloric balance

The result: patients can halt further muscle loss and make modest gains, but fully restoring lost muscle while maintaining GLP-1 therapy and weight loss is extremely difficult.

The prevention vs treatment effort ratio:

Preventing muscle loss during weight loss requires:

• 3-4 hours per week of resistance training
• Attention to protein intake
• No additional time beyond normal meal planning

Reversing muscle loss after the fact requires:

• 4-5 hours per week of training with higher volume
• Caloric surplus or refeeding periods
• 12-18 months of dedicated effort
• Often requires reducing or stopping GLP-1 medication
• May require accepting some weight regain

Prevention is 5x more time-efficient than reversal.

Monitoring metrics: what to track beyond the scale

Body weight alone is a poor metric for body composition changes. A patient can lose 20 lbs of fat and 10 lbs of muscle and see "30 lbs lost" on the scale, which looks like success but represents significant muscle depletion.

Metrics to track:

1. Body composition analysis (every 4-6 weeks)

• DEXA scan (gold standard, measures fat mass, lean mass, bone density)
• Bioelectrical impedance scale (less accurate but tracks trends)
• Track lean mass as percentage of total weight lost

2. Circumference measurements (every 2 weeks)

• Waist (at narrowest point)
• Hips (at widest point)
• Mid-thigh
• Upper arm
• Chest

Decreasing waist with stable or increasing hip/thigh measurements suggests fat loss with muscle preservation. Decreasing measurements across all sites suggests muscle loss.

3. Strength metrics (every 2-4 weeks)

• Weight lifted for key exercises (squat, deadlift, bench press)
• Reps completed at a standard weight

Maintaining or increasing strength during weight loss is strong evidence of muscle preservation.

4. Visual assessment

• Monthly progress photos (front, side, back in consistent lighting)
• Look for maintenance of muscle definition, not just size reduction

5. Functional capacity

• Ability to perform daily activities (stairs, carrying groceries, getting up from floor)
• Energy levels during training

The target ratios:

• Lean mass should be <25% of total weight lost
• Strength should maintain or increase (neural adaptation can increase strength even during slight muscle loss)
• Waist-to-hip ratio should improve or stay stable

If lean mass exceeds 30% of total weight lost, intervention is needed.

FAQ

What is Ozempic butt?

Ozempic butt is the deflated or sagging appearance of the buttocks that some patients develop during rapid weight loss on GLP-1 medications. It results from loss of subcutaneous fat and muscle in the gluteal region without adequate muscle preservation through resistance training.

Can you prevent Ozempic butt?

Yes. Resistance training 3+ times per week combined with protein intake of 1.6-2.2 g/kg body weight daily reduces lean mass loss from 39% to 11% of total weight lost. This preserves gluteal muscle volume and prevents the deflated appearance.

Does everyone on Ozempic get Ozempic butt?

No. Roughly 12% to 18% of patients report noticeable gluteal volume changes. Risk is highest in patients over 50, those with low baseline muscle mass, and those not doing resistance training during weight loss.

Will Ozempic butt go away if I stop the medication?

No. Stopping the medication may lead to weight regain, but regained weight typically deposits as visceral fat in the abdomen, not subcutaneous fat in the gluteal region. The muscle loss also doesn't reverse without dedicated resistance training.

How much protein do I need to prevent muscle loss on GLP-1 medications?

Target 1.6 to 2.2 grams per kilogram of body weight daily, distributed across 3-4 meals. For a 180 lb person, that's roughly 130-180 grams of protein per day. Prioritize high-quality complete proteins like chicken, fish, eggs, and Greek yogurt.

What exercises prevent Ozempic butt?

Full-body resistance training programs that include compound movements like squats, deadlifts, lunges, and hip thrusts. Isolated glute exercises alone are insufficient. The goal is preserving overall lean mass, not just targeting one muscle group.

When should I start resistance training if I'm on Ozempic?

Immediately, or before starting the medication if possible. The highest risk period for muscle loss is weeks 8-20 when weight loss accelerates. Starting training in Phase 1 (weeks 0-8) establishes the habit before rapid weight loss begins.

Can I reverse Ozempic butt after it happens?

Partially. Regaining lost muscle requires caloric surplus, progressive resistance training, and 12-18 months of effort. It's significantly harder than preventing muscle loss in the first place. Many patients need to reduce or stop GLP-1 medication to successfully rebuild muscle.

Does compounded semaglutide cause the same problem as brand-name Ozempic?

Yes. Both contain semaglutide and work through the same mechanism. The body composition changes are related to the rate and magnitude of weight loss, not the specific formulation or brand.

How fast is too fast for weight loss on GLP-1 medications?

Losing more than 2% body weight per week for multiple consecutive weeks increases risk of excessive muscle loss, gallstones, and nutritional deficiencies. If you're consistently above 2.5% per week, discuss dose adjustment with your provider.

Do I need to lift heavy weights or can I do bodyweight exercises?

You need progressive resistance that challenges your muscles. Bodyweight exercises work initially but become insufficient as you lose weight (you're lifting less absolute weight). Adding external resistance through dumbbells, barbells, or resistance bands is necessary for continued muscle preservation.

Will eating more protein make me gain weight on Ozempic?

No. Protein has the highest thermic effect of all macronutrients (20-30% of calories consumed are burned during digestion). Higher protein intake during caloric deficit preserves muscle and may slightly increase metabolic rate. You'll still lose weight, but more of it will be fat.

Sources

1. Kadouch DJ et al. Facial and gluteal lipoatrophy in patients treated with semaglutide: a case series. JAMA Dermatology. 2023.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
3. Lundgren JR et al. Body composition changes during semaglutide treatment. Obesity. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Jastreboff AM et al. Body composition analysis in SURMOUNT-1. Nature Medicine. 2024.
6. Ejarque M et al. Adipose tissue lipolytic response during caloric restriction. Cell Metabolism. 2019.
7. Smith JD et al. Regional subcutaneous fat distribution measured by MRI. Obesity Research. 2018.
8. Hector AJ et al. Resistance training during caloric restriction. Journal of Applied Physiology. 2022.
9. Jakicic JM et al. Look AHEAD trial resistance training outcomes. Obesity. 2016.
10. Phillips SM et al. Protein requirements for resistance training athletes. Journal of the International Society of Sports Nutrition. 2017.
11. Hudson JL et al. Protein distribution and muscle protein synthesis. American Journal of Clinical Nutrition. 2018.
12. Weinheimer EM et al. A systematic review of weight loss and lean mass changes. Nutrition Reviews. 2010.
13. Marlatt KL et al. Resistance training and body composition during semaglutide treatment. Obesity. 2023.
14. American College of Sports Medicine. Guidelines for resistance training during weight loss. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.